Multiple sclerosis therapy: US, EU regulators accept marketing applications for siponimod

Written by Naamah Maundrell, Future Science Group

Novartis (Basel, Switzerland) have announced US FDA and EMA filing acceptance for their new drug application and marketing authorization application of siponimod to treat secondary progressive multiple sclerosis (SPMS) in adults. The filing application was supported by Phase III EXPAND data, which demonstrated siponimod to have beneficial effects on disability, relapses and magnetic resonance imaging disease activities in individuals with SPMS. Bruce Bebo, Executive Vice President Research, National MS Society (NC, USA) commented: “We are excited to see a potential new treatment on the horizon. It is a significant milestone in our unrelenting search for treatments that can benefit adults...

To view the full article, please register now for access

It's completely free